Cell transplantation is now being explored as a new therapeutic strategy to restore function in the diseased human central nervous system. Neural grafts show long-term survival and function in patients with Parkinson's disease but the symptomatic relief needs to be increased. Cell transplantation seems justified in patients with Huntington's disease and, at a later stage, possibly also in demyelinating disorders. The further development in this research field will require systematic studies in animal experiments but also well-designed clinical trials in small groups of patients.
BacklundE.-O.; GranbergP.-O.; HambergerB.; KnutssonE.; MårtenssonA.; SedvallG.; SeigerÅ.; OlsonL.Transplantation of adrenal medullary tissue to striatum in parkinsonism.First clinical trials. J. Neurosurg.62: 169–173; 1985.
3.
BjörklundA.; SteneviU.Reconstruction of the nigrostriatal pathway by intracerebral nigral transplants.Brain Res.177: 555–560; 1979.
4.
BjörklundA.; SteneviU.Intracerebral neural grafting: A historical perspective. In: BjörklundA.; SteneviU., eds. Neural grafting in the mammalian CNS.Elsevier: Amsterdam;1985: 3–14.
5.
BrundinP.; StreckerR.E.; WidnerH.; ClarkeD.J.; NilssonO.G.; ÅstedtB.; LindvallO.; BjörklundA.Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Immunological aspects, spontaneous and drug-induced behaviour, and dopamine release.Exp. Brain. Res.70: 192–208; 1988.
6.
DunnettS.B.Transplantation of embryonic dopamine neurons: What we know from rats.J. Neurol.238: 65–74; 1991.
7.
DunnettS.B.; AnnettL.E.Nigral transplants in primate models of parkinsonism. In: LindvallO.; BjörklundA.; WidnerH., eds. Intracerebral transplantation in movement disorders. Experimental basis and clinical experiences.Amsterdam: Elsevier Science Publishers;1991: 27–51.
8.
FisherL.J.; JinnahH.; A; KaleL.C.; HigginsG.A.; GageF.H.Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa.Neuron6: 371–380; 1991.
9.
FreedC.R.; BreezeR.E.; RosenbergN.L.; SchneckS.A.; WellsT.H.; BarrettJ.N.; GraftonS.T.; HuangS.C.; EidelbergD.; RottenbergD.A.Transplantation of human fetal dopamine cells for Parkinson's disease: Results at 1 year.Arch. Neurol.47: 505–512; 1990.
10.
FreedC.R.; BreezeR.E.; RosenbergN.L.; SchneckS.A.; KriekE.; QiJ.; LoneT.; ZhangY.; SnyderJ.A.; WellsT.H.; Olson RamigL.; ThompsonL.; MazziottaJ.C.; HuangS.C.; GraftonS.T.; BrooksD.; SawleG.; SchroterG.; AnsariA.A.Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease.N. Engl. J. Med.327: 1549–1555; 1992.
11.
GoetzC.G.; StebbinsG.T.; KlawansH.L.III; RollerW.C.; GrossmanR.G.; BakayR.A.E.; PennR.D.United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: Presurgical, and 1- and 2-year follow-up.Neurology41: 1719–1722; 1991.
12.
HendersonB.T.H.; CloughC.; G; HughesR.C.; HitchcockE.R.; KennyB. G.Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease.Arch. Neurol.48: 822–827; 1991.
13.
HorellouP.; BrundinP.; KalénP.; MalletJ.; BjörklundA.In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated rat striatum.Neuron5: 393–402; 1990.
14.
HymanC.; HoferM.; BardeY.-A.; JuhaszM.; YancopoulosG.D.; SquintoS.P.; LindsayR.M.BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.Nature350: 230–232; 1991.
15.
JiaoS.; GurevichV.; WolffJ.A.Long-term correction of rat model of Parkinson's disease by gene therapy.Nature362: 450–453; 1993.
16.
KnüselB.; WinslowJ.W.; RosenthalA.; BurtonL.E.; SeidD.P.; NikolicsK.; HeftiF.Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.Proc. Natl. Acad. Sci. USA88: 961–965; 1991.
17.
LinL.F.; DohertyD.H.; LileJ.D.; BekteshS.; CollinsF.GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.Science260: 1130–1132; 1993.
18.
LindvallO.; BacklundE.-O.; FardeL.; SedvallG.; FreedmanR.; HofferB.; NobinA.; SeigerÅ.; OlsonL.Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to putamen.Ann. Neurol.22: 457–468; 1987.
19.
LindvallO.; RehncronaS.; BrundinP.; GustaviiB.; ÅstedtB.; WidnerH.; LindholmT.; BjörklundA.; LeendersK.L.; RothwellJ.C.; FrackowiakR.; MarsdenC.D.; JohnelsB.; StegG.; FreedmanR.; HofferB.J.; SeigerÅ.; BygdemanM.; StrömbergI.; OlsonL.Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6 month follow-up.Arch. Neurol.46: 615–631; 1989.
20.
LindvallO.; BrundinP.; WidnerH.; RehncronaS.; GustaviiB.; FrackowiakR.; LeendersK.L.; SawleG.; RothwellJ.C.; MarsdenC.D.; BjörklundA.Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease.Science247: 574–577; 1990.
21.
LindvallO.; WidnerH.; RehncronaS.; BrundinP.; OdinP.; GustaviiB.; FrackowiakR.; LeendersK.L.; SawleG.; RothwellJ.C.; BjörklundA.; MarsdenC.D.Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants.Ann. Neurol.31: 155–165; 1992.
22.
LindvallO.; SawleG.; WidnerH.; RothwellJ.C.; BjörklundA.; BrooksD.; BrundinP.; FrackowiakR.; MarsdenC.D.; OdinP.; RehncronaS.Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease.Ann. Neurol.35: 172–180; 1994.
23.
LindvallO., ed. Restoration of brain function by tissue transplantation.Berlin Heidelberg: Springer; 1993: 1–74.
24.
López-LozanoJ.J.; BravoG.; BreraB.; UríaJ.; DargalloJ.; SalmeanJ.; InsaustiJ.; CerrolazaJ.; and CPH Neural Transplantation Group. Can an analogy be drawn between the clinical evolution of Parkinson's patients who undergo autoimplantation of adrenal medulla and those of fetal ventral mesencephalon transplant recipients? In: LindvallO.; BjörklundA.; WidnerH., eds. Intracerebral transplantation in movement disorders. Experimental basis and clinical experiences.Amsterdam: Elsevier;1991: 87–98.
25.
MadrazoI.; Franco-BourlandR.; Ostrosky-SolisF.; AguileraM.; CuevasC.; ZamoranoC.; MorelosA.; MagallonE.; Guizar-SahagunG.Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of Parkinsonian subjects.Arch. Neurol.47: 1281–1285; 1990.
26.
MadrazoI.; Drucker-ColinR.; DiazV.; Martinez-MartaJ.; TorresC.; BecerrilJ.J.Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease.N. Engl. J. Med.316: 831–834; 1987.
27.
MolinaH.; QuiñonesR.; AlvarezL.; GalarragaJ.; PiedraJ.; SuárezC.; RachidM.; GarcíaJ.C.; PerryT.L.; SantanaA.; CarmenateH.; MacíasR.; TorresO.; RojasM.J.; CùrdovaF.; MuñozJ.L.Transplantation of human fetal mesencephalic tissue in caudate nucleus as treatment for Parkinson's disease: The Cuban experience. In: LindvallO.; BjörklundA.; WidnerH., eds. Intracerebral transplantation in movement disorders. Experimental basis and clinical experiences.Amsterdam: Elsevier;1991: 99–110.
28.
OlsonL.; BacklundE.-O.; EbendalT.; FreedmanR.; HambergerB.; HanssonP.; HofferB.; LindblomU.; MeyersonB.; StrömbergI.; SydowO.; SeigerÅ.Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial.Arch. Neurol.48: 373–381; 1991.
29.
PerlowM.J.; FreedW.J.; HofferB.J.; SeigerÅ.; OlsonL.; WyattR.J.Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system.Science204: 643–647; 1979.
30.
PeschanskiM.; DeferG.; N'GuyenJ.P.; RicolfiF.; MonfortJ.C.; RemyP.; GenyC.; SamsonY.; HantrayeP.; JenyR.; GastonA.; KéravelY.; DegosJ.D.; CesaroP.Bilateral motor improvement and alteration of L-dopa effect on two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.Brain117: 487–499; 1994.
31.
SawleG.V.; BloomfieldP.M.; BjörklundA.; BrooksD.J.; BrundinP.; LeendersK.L.; LindvallO.; MarsdenC.; D; RehncronaS.; WidnerH.; FrackowiakR.S.J.Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]-6-L-fluorodopa studies in two patients with putaminal implants.Ann. Neurol.31: 166–173; 1992.
32.
SpencerD.D.; RobbinsR.J.; NaftolinF.; MarekK.L.; VollmerT.; LeranthC.; RothR.H.; PriceL.H.; GjeddeA.; BunneyB.S.; SassK.J.; ElsworthJ.D.; KierE.L.; MakuchR.; HofferP.B.; RedmondD.E.Jr.Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.N. Engl. J. Med.327: 1541–1548; 1992.
33.
StrömbergL.; Herrera-MarschitzM.; UngerstedtU.; EbendalT.; OlsonL.Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior.Exp. Brain. Res.60: 335–349; 1985.
34.
WidnerH.; TetrudJ.; RehncronaS.; SnowB.; BrundinP.; GustaviiB.; BjörklundA.; LindvallO.; LangstonJ.W.Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).N Engl. J. Med.327: 1556–1563; 1992.
35.
WolffJ.A.; FisherL.; J; XuL.; JinnahH.A.; LanglaisP.J.; IuvoneP.M.; O'MalleyK.L.; RosenbergM.B.; ShimohamaS.; FriedmannT.; GageF.H.Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.Proc. Natl. Acad. Sci. USA86: 9011–9014; 1989.
